Shopping Cart
- Remove All
Your shopping cart is currently empty
Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.13480-84-5

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $146 | In Stock | |
| 5 mg | $350 | In Stock | |
| 10 mg | $530 | In Stock | |
| 25 mg | $859 | In Stock | |
| 50 mg | $1,180 | In Stock | |
| 100 mg | $1,590 | In Stock | |
| 500 mg | $3,190 | In Stock |
| Description | Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.13480-84-5 |
| In vivo | Iroxanadine improves the survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. The addition of Iroxanadine (0.1-1 μM) to the culture medium prior to hypoxia or at the start of reoxygenation significantly reduced the caspase-dependent apoptosis.[1] |
| Synonyms | BRX-235, BRX235, BRX-005, BRX005, BRX 235, BRX 005 |
| Molecular Weight | 260.33 |
| Formula | C14H20N4O |
| Cas No. | 203805-20-3 |
| Smiles | C(C1NC(=NOC1)C=2C=CC=NC2)N3CCCCC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (172.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.